FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer
0:00
2:59
FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer
Flere episoder fra "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Gå ikke glip af nogen episoder af “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” - abonnér på podcasten med gratisapp GetPodcast.